Showing results (1-10 of 26) with videos related to
Sort By:
Pageof 3
Studies in Health Technology and Informatics|March 8, 2005
Bioavailability and bioequivalence trials: statistics & pharmacokinetic principlesLakshminarayan Rajaram, Sandip K Roy, Andrej SkerjanecJournal of Clinical Pharmacology|November 27, 2009
Investigation of the pharmacokinetic interactions of deferasirox, a once-daily oral iron chelator, with midazolam, rifampin, and repaglinide in healthy volunteersAndrej Skerjanec, Jixian Wang, Kelly Maren, et al.The AAPS Journal|March 9, 2018
Application of Pharmacometric Analysis in the Design of Clinical Pharmacology Studies for Biosimilar DevelopmentPeijuan Zhu, Sherwin K B Sy, Andrej SkerjanecClinical Therapeutics|September 22, 2014
Pharmacokinetic and pharmacodynamic characteristics of single-dose Canakinumab in patients with type 2 diabetes mellitusAdele Noe, Campbell Howard, Tom Thuren, et al.British Journal of Clinical Pharmacology|August 7, 2018
Proposed biosimilar pegfilgrastim shows similarity in pharmacokinetics and pharmacodynamics to reference pegfilgrastim in healthy subjectsRoumen Nakov, Sreekanth Gattu, Jessie Wang, et al.Clinical Drug Investigation|September 14, 2013
Bioequivalence of canakinumab liquid pre-filled syringe and reconstituted lyophilized formulations following 150 mg subcutaneous administration: a randomized study in healthy subjectsAndrea Chioato, Emanuele Noseda, Laurence Colin, et al.Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 16, 2008
Biodistribution and plasma protein binding of zoledronic acidH Markus Weiss, Ulrike Pfaar, Alain Schweitzer, et al.Cardiovascular Diabetology|June 3, 2014
Safety and tolerability of canakinumab, an IL-1β inhibitor, in type 2 diabetes mellitus patients: a pooled analysis of three randomised double-blind studiesCampbell Howard, Adele Noe, Andrej Skerjanec, et al.Expert Opinion on Biological Therapy|April 20, 2019
Differences in immunogenicity associated with non-product related variability: insights from two pharmacokinetic studies using GP2017, an adalimumab biosimilarOliver von Richter, Lena Lemke, Halimuniyazi Haliduola, et al.Pageof 3